Author: Ravi Shankar

Consistency Continues with 19% Revenue Growth and Expanding Profitability

SANTA BARBARA, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) — AppFolio, Inc. (NASDAQ: APPF) (“AppFolio” or the “Company”), a technology leader powering the future of the real estate industry, today announced its financial results for the third quarter ended September 30, 2026.

“Q3 reflects the strength and durability of our business, as new and existing customers continue to adopt our performance platform,” said Shane Trigg, Chairman and CEO. “The promise of Real Estate Performance Management is helping create a future of winning with our customers, turning performance into a competitive advantage that compounds over time.”

Financial Highlights for Third Quarter of 2026

• Revenue grew 19% year-over-year to $296 million.
• Total units under management grew 8% year-over-year to 9.8 million.
• GAAP operating income grew 64% to $57 million, or 19.4% of revenue, compared to $35 million, or 14.1% of revenue in Q3 2025.
• Non-GAAP operating income grew 38% to $81 million, or 27.3% of revenue, compared to $59 million, or 23.5% of revenue in Q3 2025.
• Net cash provided by operating activities was $97 million, or 32.7% of revenue, compared to $86 million, or 34.5% of revenue in Q3 2025.

Financial Outlook
Based on information available as of October 22, 2026, AppFolio’s outlook for fiscal year 2026 follows:

• Full year revenue range is increasing to $1.122 – $1.127 billion.
• Full year non-GAAP operating margin range as a percentage of revenue is now 26.5% – 27.5%.
• Diluted weighted average shares outstanding are expected to be approximately 36 million for the full year.

Conference Call Information
As previously announced, the Company will host a conference call today, October 22, 2026, at 2:00 p.m. Pacific Time (PT), 5:00 p.m. Eastern Time (ET), to discuss the Company’s third quarter financial results. A live webcast of the call will be available at: https://edge.media-server.com/mmc/p/jcjgqabv. To access the call by phone, please go to the following link: https://register-conf.media-server.com/register/BI59a3520d44444834b693d21914243efb, and you will be provided with dial-in details. A replay of the webcast will also be available for a limited time on AppFolio’s Investor Relations website at https://ir.appfolioinc.com/news-events/events.

The Company also provides announcements regarding its financial results and other matters, including SEC filings, investor events, and press releases, on its Investor Relations website at https://ir.appfolioinc.com/, as a means of disclosing material nonpublic information and for complying with AppFolio’s disclosure obligations under Regulation FD.

About AppFolio
AppFolio is a technology leader powering the future of the real estate industry. Our innovative platform and trusted partnership enable our customers to connect communities, increase operational efficiency, and grow their business. For more information about AppFolio, visit ir.appfolioinc.com.

Investor Relations Contact:
Lori Barker
ir@appfolio.com 

Use of Non-GAAP Financial Measures
Reconciliations of current and historical non-GAAP financial measures to AppFolio’s financial results as determined in accordance with GAAP are included at the end of this press release following the accompanying financial data. For a description of these non-GAAP financial measures, including the reasons management uses each measure, please see the section of the tables entitled “Statement Regarding the Use of Non-GAAP Financial Measures.”

AppFolio is unable, at this time, to provide GAAP equivalent guidance measures on a forward-looking basis for non-GAAP operating margin because certain items that impact this measure are uncertain, out of our control, or cannot be reasonably predicted, such as charges related to stock-based compensation expense. The effect of these excluded items may be significant.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which statements are subject to considerable risks and uncertainties. Forward-looking statements include all statements that are not statements of historical fact contained in this press release, and can be identified by words such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “future’” “predicts, “projects,” “target,” “seeks,” “contemplates,” “should,” “will,” “would” or similar expressions and the negatives of those expressions. In particular, forward-looking statements contained in this press release relate to future operating results and financial position, including the Company’s fiscal year 2026 financial outlook, anticipated future expenses and investments, the Company’s business opportunities, the impact of the Company’s strategic actions and initiatives, the potential benefits and effect of AI and its impact on the Company’s plans, objectives, expectations and capabilities.

Forward-looking statements represent AppFolio’s current beliefs and expectations based on information currently available and speak only as of the date the statement is made. Forward-looking statements are subject to numerous known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. The risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to materially differ from those expressed or implied by these forward-looking statements include those risks, uncertainties and other factors described in the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, which was filed with the SEC on February 5, 2026, as such risk factors may be updated from time to time in our subsequent filings with the SEC, and the section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s most recently filed Annual Report on Form 10-K or Quarterly Report on Form 10-Q, as well as in the Company’s other filings with the SEC. You should read this press release with the understanding that the Company’s actual future results may be materially different from the results expressed or implied by these forward-looking statements.

The Company undertakes no obligation to update any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (in thousands)
		September 30, 2026			December 31, 2025
Assets
Current assets
Cash and cash equivalents		$	258,536		$	106,967
Investment securities—current			48,740			144,256
Accounts receivable, net			52,535			36,873
Prepaid expenses and other current assets			47,561			65,218
Total current assets			407,372			353,314
Property and equipment, net			20,316			23,228
Operating lease right-of-use assets			14,227			15,924
Capitalized software development costs, net			11,122			11,324
Goodwill			96,410			96,410
Intangible assets, net			31,153			38,826
Deferred income taxes			32,210			58,823
Long-term investments			87,668			77,033
Other long-term assets			15,193			14,085
Total assets		$	715,671		$	688,967
Liabilities and Stockholders’ Equity
Current liabilities
Accounts payable		$	5,656		$	4,123
Accrued employee expenses			43,071			59,774
Accrued expenses			28,679			20,829
Other current liabilities			24,476			22,121
Total current liabilities			101,882			106,847
Operating lease liabilities			24,876			33,287
Other liabilities			6,399			6,254
Total liabilities			133,157			146,388
Stockholders’ equity			582,514			542,579
Total liabilities and stockholders’ equity		$	715,671		$	688,967

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (in thousands, except per share amounts)
	Three Months Ended September 30,								Nine Months Ended September 30,
		2026				2025				2026			2025
Revenue(1)	$	295,691			$	249,353			$	839,029		$	702,630
Costs and operating expenses:
Cost of revenue (exclusive of depreciation and amortization)(2)		105,580				91,476				303,150			254,801
Sales and marketing(2)		48,623				35,912				130,068			103,745
Research and product development(2)		53,128				54,037				153,754			144,469
General and administrative(2)		25,953				27,446				75,920			72,733
Depreciation and amortization		4,996				5,436				15,001			17,541
Total costs and operating expenses		238,280				214,307				677,893			593,289
Income from operations		57,411				35,046				161,136			109,341
Other (loss) income, net		(1	)			(4	)			567			41
Interest income, net		2,204				1,690				5,423			6,109
Income before provision for income taxes		59,614				36,732				167,126			115,491
Provision for income taxes		13,636				3,086				37,180			14,482
Net income	$	45,978			$	33,646			$	129,946		$	101,009
Net income per common share:
Basic	$	1.30			$	0.94			$	3.66		$	2.80
Diluted	$	1.29			$	0.93			$	3.65		$	2.78
Weighted average common shares outstanding
Basic		35,436				35,889				35,507			36,036
Diluted		35,578				36,259				35,616			36,368

⁽¹⁾ The following table presents our revenue categories:

	Three Months Ended September 30,						Nine Months Ended September 30,
		2026			2025			2026			2025
Subscription Services	$	61,525		$	53,752		$	179,547		$	155,738
Value Added Services		231,948			192,092			652,778			536,943
Other		2,218			3,509			6,704			9,949
Total revenue	$	295,691		$	249,353		$	839,029		$	702,630

⁽²⁾ Includes stock-based compensation expense as follows:

	Three Months Ended September 30,						Nine Months Ended September 30,
		2026			2025			2026			2025
Costs and operating expenses:
Cost of revenue (exclusive of depreciation and amortization)	$	1,315		$	1,241		$	3,649		$	3,947
Sales and marketing		3,586			3,443			10,559			9,336
Research and product development		8,839			9,076			25,639			24,182
General and administrative		6,860			7,033			19,213			17,998
Total stock-based compensation expense	$	20,600		$	20,793		$	59,060		$	55,463

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (in thousands)
	Three Months Ended September 30,								Nine Months Ended September 30,
		2026				2025				2026				2025
Cash from operating activities
Net income	$	45,978			$	33,646			$	129,946			$	101,009
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		4,996				5,436				15,001				17,541
Amortization of operating lease right-of-use assets		572				517				1,698				1,525
Gain on lease termination and modification		(1,547	)			—				(1,547	)			—
Amortization of costs capitalized to obtain revenue contracts, net		3,428				2,768				9,896				8,187
Deferred income taxes		10,609				30,303				26,613				17,118
Stock-based compensation, including as amortized		20,600				20,793				59,060				55,463
Other		3				(233	)			(520	)			(1,281	)
Changes in operating assets and liabilities:
Accounts receivable		(2,094	)			(1,803	)			(16,012	)			(10,000	)
Prepaid expenses and other assets		160				(4,251	)			(9,933	)			(15,677	)
Accounts payable		881				894				1,534				1,746
Operating lease liabilities		(4,941	)			(1,075	)			(7,325	)			(3,177	)
Accrued expenses and other liabilities		18,121				(988	)			10,257				4,661
Net cash provided by operating activities		96,766				86,007				218,668				177,115
Cash from investing activities
Purchases of available-for-sale investments		(46,195	)			(102,541	)			(92,135	)			(166,575	)
Proceeds from sales of available-for-sale investments		—				—				140,154				202,662
Proceeds from maturities of available-for-sale investments		1,810				32,800				47,400				76,620
Purchases of property and equipment		(14	)			(1,336	)			(242	)			(1,841	)
Proceeds from sale of property and equipment		75				—				75				—
Capitalization of software development costs		(983	)			(936	)			(3,537	)			(2,414	)
Purchases of long-term investments		—				—				(10,000	)			(75,000	)
Cash paid in business acquisition, net of cash acquired		—				—				—				(906	)
Net cash (used in) provided by investing activities		(45,307	)			(72,013	)			81,715				32,546
Cash from financing activities
Proceeds from stock option exercises and the issuance of common stock under the Employee Stock Purchase Plan		1,084				953				2,082				1,081
Tax withholding for net share settlement		(7,228	)			(12,332	)			(21,706	)			(31,430	)
Purchase of common stock		(4,180	)			—				(129,190	)			(145,723	)
Net cash used in financing activities		(10,324	)			(11,379	)			(148,814	)			(176,072	)
Net increase in cash, cash equivalents and restricted cash		41,135				2,615				151,569				33,589
Cash, cash equivalents and restricted cash
Beginning of period		217,651				73,728				107,217				42,754
End of period	$	258,786			$	76,343			$	258,786			$	76,343

		RECONCILIATION FROM GAAP TO NON-GAAP RESULTS (UNAUDITED) (in thousands, except per share data)
			Three Months Ended September 30,								Nine Months Ended September 30,
				2026				2025				2026				2025
Costs and operating expenses:
	GAAP cost of revenue (exclusive of depreciation and amortization)		$	105,580			$	91,476			$	303,150			$	254,801
		Stock-based compensation expense		(1,315	)			(1,241	)			(3,649	)			(3,947	)
	Non-GAAP cost of revenue (exclusive of depreciation and amortization)		$	104,265			$	90,235			$	299,501			$	250,854
	GAAP cost of revenue (exclusive of depreciation and amortization) as a percentage of revenue			36	%			37	%			36	%			36	%
	Non-GAAP cost of revenue (exclusive of depreciation and amortization) as a percentage of revenue			35	%			36	%			36	%			36	%
	GAAP sales and marketing		$	48,623			$	35,912			$	130,068			$	103,745
		Stock-based compensation expense		(3,586	)			(3,443	)			(10,559	)			(9,336	)
	Non-GAAP sales and marketing		$	45,037			$	32,469			$	119,509			$	94,409
	GAAP sales and marketing as a percentage of revenue			16	%			14	%			16	%			15	%
	Non-GAAP sales and marketing as a percentage of revenue			15	%			13	%			14	%			13	%
	GAAP research and product development		$	53,128			$	54,037			$	153,754			$	144,469
		Stock-based compensation expense		(8,839	)			(9,076	)			(25,639	)			(24,182	)
	Non-GAAP research and product development		$	44,289			$	44,961			$	128,115			$	120,287
	GAAP research and product development as a percentage of revenue			18	%			22	%			18	%			21	%
	Non-GAAP research and product development as a percentage of revenue			15	%			18	%			15	%			17	%
	GAAP general and administrative		$	25,953			$	27,446			$	75,920			$	72,733
		Stock-based compensation expense		(6,860	)			(7,033	)			(19,213	)			(17,998	)
	Non-GAAP general and administrative		$	19,093			$	20,413			$	56,707			$	54,735
	GAAP general and administrative as a percentage of revenue			9	%			11	%			9	%			10	%
	Non-GAAP general and administrative as a percentage of revenue			6	%			8	%			7	%			8	%
	GAAP depreciation and amortization		$	4,996			$	5,436			$	15,001			$	17,541
		Amortization of stock-based compensation capitalized in software development costs		(153	)			(241	)			(634	)			(723	)
		Amortization of purchased intangibles		(2,558	)			(2,558	)			(7,673	)			(7,673	)
	Non-GAAP depreciation and amortization		$	2,285			$	2,637			$	6,694			$	9,145
	GAAP depreciation and amortization as a percentage of revenue			2	%			2	%			2	%			2	%
	Non-GAAP depreciation and amortization as a percentage of revenue			1	%			1	%			1	%			1	%

			Three Months Ended September 30,								Nine Months Ended September 30,
				2026				2025				2026				2025
Income from operations:
	GAAP income from operations		$	57,411			$	35,046			$	161,136			$	109,341
		Stock-based compensation expense		20,600				20,793				59,060				55,463
		Amortization of stock-based compensation capitalized in software development costs		153				241				634				723
		Amortization of purchased intangibles		2,558				2,558				7,673				7,673
	Non-GAAP income from operations		$	80,722			$	58,638			$	228,503			$	173,200
Operating margin:
	GAAP operating margin			19.4	%			14.1	%			19.2	%			15.6	%
		Stock-based compensation expense as a percentage of revenue		7.0				8.3				7.0				7.9
		Amortization of stock-based compensation capitalized in software development costs as a percentage of revenue		—				0.1				0.1				0.1
		Amortization of purchased intangibles as a percentage of revenue		0.9				1.0				0.9				1.1
	Non-GAAP operating margin			27.3	%			23.5	%			27.2	%			24.7	%
Net income (loss):
	GAAP net income		$	45,978			$	33,646			$	129,946			$	101,009
		Stock-based compensation expense		20,600				20,793				59,060				55,463
		Amortization of stock-based compensation capitalized in software development costs		153				241				634				723
		Amortization of purchased intangibles		2,558				2,558				7,673				7,673
		Income tax effect of adjustments		(4,608	)			(9,582	)			(14,408	)			(23,182	)
	Non-GAAP net income		$	64,681			$	47,656			$	182,905			$	141,686
Net income per share, basic:
	GAAP net income per share, basic		$	1.30			$	0.94			$	3.66			$	2.80
		Non-GAAP adjustments to net income		0.53				0.39				1.49				1.13
	Non-GAAP net income per share, basic		$	1.83			$	1.33			$	5.15			$	3.93
Net income per share, diluted:
	GAAP net income per share, diluted		$	1.29			$	0.93			$	3.65			$	2.78
		Non-GAAP adjustments to net income		0.53				0.38				1.49				1.12
	Non-GAAP net income per share, diluted		$	1.82			$	1.31			$	5.14			$	3.90
	Weighted-average shares used in GAAP and non-GAAP per share calculation
		Basic		35,436				35,889				35,507				36,036
		Diluted		35,578				36,259				35,616				36,368

Statement Regarding the Use of Non-GAAP Financial Measures

We use the following non-GAAP financial measures in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP.

• Non-GAAP presentation of income from operations, costs and operating expenses, operating margin, net income, and net income per share. These measures exclude certain non-cash or non-recurring items, including stock-based compensation expense, amortization of stock-based compensation capitalized in software development costs, amortization of purchased intangibles, and the related income tax effect of these adjustments, as applicable and described below. Non-GAAP operating margin is calculated as non-GAAP operating income from operations as a percentage of revenue.

We use each of these non-GAAP financial measures internally to assess and compare operating results across reporting periods, for internal budgeting and forecasting purposes, and to evaluate our financial performance. We believe these non-GAAP financial measures also provide useful supplemental information to investors and facilitate the analysis of our operating results and comparison of operating results across reporting periods.

In particular, we believe these non-GAAP financial measures are useful to investors and others in assessing our operating performance due to the following factors:

• Stock-based compensation expense and amortization of stock-based compensation capitalized in software development costs. We utilize stock-based compensation to attract and retain employees. It is principally aimed at aligning their interests with those of our stockholders while ensuring long-term retention, rather than to address operational performance for any particular period. As a result, stock-based compensation expenses vary for reasons that are generally unrelated to financial and operational performance in any particular period.

• Amortization of purchased intangibles. We view amortization of purchased intangible assets as items arising from pre-acquisition activities determined at the time of an acquisition. While these intangible assets are evaluated for impairment regularly, amortization of the cost of purchased intangibles is an expense that is not typically affected by operations during any particular period.

• Income tax effects of adjustments. We utilize a fixed long-term projected tax rate in our computation of non-GAAP income tax effects to provide better consistency across interim reporting periods. In projecting this long-term non-GAAP tax rate, we utilize a financial projection that excludes the direct impact of other non-GAAP adjustments. The projected rate, which we have determined to be 22% and 21% for 2026 and 2025, respectively, considers other factors such as our current operating structure, existing tax positions in various jurisdictions, and key legislation in major jurisdictions where we operate. We periodically re-evaluate this tax rate, as necessary, for significant events, based on relevant tax law changes, and material changes in the forecasted geographic earnings mix.

Our non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in our industry, as other companies may calculate non-GAAP financial results differently. In addition, there are limitations in using non-GAAP financial measures because non-GAAP financial measures are not prepared in accordance with GAAP and can exclude expenses that may have a material impact on our reported financial results. As such, non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. A reconciliation of the historical non-GAAP financial measures to their most directly comparable GAAP measures has been provided in the tables above. We encourage investors to review the reconciliation of these historical non-GAAP financial measures to their most directly comparable GAAP financial measures.

Southfield, Michigan, Oct. 22, 2026 (GLOBE NEWSWIRE) — Credit Acceptance Corporation (Nasdaq: CACC) (referred to as the “Company”, “Credit Acceptance”, “we”, “our”, or “us”) announced today that we expect to issue a news release with our third quarter 2026 earnings on Thursday, October 29, 2026, after the market closes. A webcast is scheduled for Thursday, October 29, 2026, at 5:00 p.m. Eastern Time to discuss third quarter 2026 earnings.  

Conference Call and Webcast Information:
Date: Thursday, October 29, 2026
Time: 5:00 p.m. Eastern Time

Telephone Access: 

Only persons accessing the webcast by telephone will be able to pose questions to the presenters during the webcast. To participate by telephone, you must pre-register using the following link:

https://register-conf.media-server.com/register/BIb09f4d3694a2478ba3f752ee48d8fc50

or through the link posted on the “Investor Relations” section of our website at ir.creditacceptance.com. Upon registering you will be provided with the dial-in number and a unique PIN to access the webcast by telephone.

Webcast Access:
The webcast can also be accessed live by visiting the “Investor Relations” section of our website at ir.creditacceptance.com.

Additionally, a replay and transcript of the webcast will be archived in the “Investor Relations” section of our website.

Description of Credit Acceptance Corporation

We make vehicle ownership possible by providing innovative financing solutions that enable automobile dealers to sell vehicles to consumers regardless of their credit history. Our financing programs are offered through a nationwide network of automobile dealers who benefit from sales of vehicles to consumers who otherwise could not obtain financing; from repeat and referral sales generated by these same customers; and from sales to customers responding to advertisements for our financing programs, but who actually end up qualifying for traditional financing.

Without our financing programs, consumers are often unable to purchase vehicles or they purchase unreliable ones. Further, as we report to the three national credit reporting agencies, an important ancillary benefit of our programs is that we provide consumers with an opportunity to improve their lives by improving their credit score and move on to more traditional sources of financing. Credit Acceptance is publicly traded on the Nasdaq Stock Market under the symbol CACC. For more information, visit creditacceptance.com.

CONTACT: Investor Relations: Jay Brinkley
Senior Vice President & Treasurer
(248) 353-2700 Ext. 6739
IR@creditacceptance.com

JUPITER, Fla., Oct. 22, 2026 (GLOBE NEWSWIRE) — Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its annual Investor Day will take place on Tuesday, December 8, 2026 from 10:30 a.m. to 12:00 p.m. ET at the Harvard Club of New York City at 35 West 44th Street, New York, NY 10036.

The event will include presentations from Ligand CEO Todd Davis, CFO Tavo Espinoza and other members of the Ligand senior management team. Presentations will highlight the company’s strategy, investment activity, royalty portfolio, and long-term financial outlook. Wes Kaupinen, Founder and CEO of Palvella Therapeutics, a Ligand partner, will be a guest speaker at the event and discuss the progress of QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), which is in development for the treatment of microcystic lymphatic malformations, cutaneous venous malformations, clinically significant angiokeratomas, and additional rare disease indications.

A live webcast of the event will be accessible through Ligand’s Investor Relations Events Page. A webcast replay will be available following the conclusion of the event.

Investors and analysts can register for the event here.

About Ligand
Ligand is a leading royalty aggregator, partnering with biopharmaceutical companies to finance and advance late-stage clinical development programs. Ligand owns and manages one of the largest and most diversified portfolios of biopharmaceutical royalties in the industry, with economic interests in more than 200 development and commercial-stage assets. Ligand funds high-value programs in exchange for long-term economic interests, aligning capital with clinical and commercial success. Ligand’s royalty portfolio is designed to deliver consistent and predictable revenue streams across a broad range of therapeutic assets. Ligand also licenses its proprietary technologies, Captisol® and NITRICIL™, to support drug development and formulation across its global partner network. For more information, visit www.ligand.com or follow Ligand on X and LinkedIn.

Contacts

Investors:
Melanie Herman
investors@ligand.com
(858) 550-7761

Media:
Kellie Walsh
media@ligand.com
(914) 315-6072

BEDFORD, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) — Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its third quarter 2026 financial results before the opening of the market on Friday, November 6, 2026, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights.

The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID number 27870. A live audio webcast and accompanying presentation materials will be available in the Investor Relations section of Anika’s website, www.anika.com. The call will be archived and accessible on the same website shortly after its conclusion.

About Anika

Anika Therapeutics, Inc. (NASDAQ: ANIK), is the global leader in the design, development, manufacturing, and commercialization of hyaluronic acid innovations. In partnership with clinicians, our primary focus is dedicated to delivering and advancing osteoarthritis pain management and orthopedic regenerative solutions. At our core is a passion to deliver a differentiated portfolio that improves patient outcomes around the world. Anika’s global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit www.anika.com.

ANIKA, ANIKA THERAPEUTICS and the Anika logo are trademarks of Anika Therapeutics, Inc. or its subsidiaries or are licensed to Anika Therapeutics, Inc. for its use.

For Investor Inquiries:
Anika Therapeutics, Inc.
Matt Hall, 781-457-9554
Executive Director, Corporate Development and Investor Relations
investorrelations@anika.com

MIDLAND, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) — Big Digital Energy, Inc. (“We,” “Big Digital” or the “Company”) (Nasdaq: “BGDE”), a developer and operator of next-generation digital infrastructure, today announced that it will hold its earnings conference call and webcast for the third quarter ended September 30, 2026 on Thursday, November 5^th, 2026 at 5:00 PM Eastern Time. A press release detailing these results will be issued prior to the call on the same day.

Conference Call Information:
To participate in this event, please log on or dial in approximately 5 minutes before the beginning of the call.

• Date: November 5, 2026
• Time: 5:00 PM EDT
• Participant Call Links:
  • Live Webcast: Link
  • Dial-in:
    • Toll-Free: (800) 715-9871
    • Toll: (646) 307-1963
    • Passcode: 9283304

A live and archived webcast of the conference call will be available on the Investors section of Big Digital Energy’s website at https://www.bigdigital.energy/.

About Big Digital Energy, Inc.
Big Digital Energy, Inc. (Nasdaq: “BGDE”) is a U.S.-based technology company that designs, builds, and operates next-generation digital infrastructure platforms. The Company provides services spanning artificial intelligence (“AI”), high-performance computing (“HPC”), digital assets (including Bitcoin mining), and other intensive compute applications. The Company delivers both self-mining operations and colocation/hosting for enterprise customers, with a vertically integrated infrastructure model built for scalability and efficiency.

A core part of the Company’s strategy is identifying and advancing sites positioned to support high-performance compute with the infrastructure required for long-term deployment. With approximately 169 megawatts of energized capacity and additional capacity under development, the Company is positioning itself as a competitive provider of digital infrastructure solutions to support the demand for AI data centers.

CONTACT
Investor Relations: IR@bigdigital.energy
Partnerships: Partnerships@bigdigital.energy
Media and Press: mediarelations@bigdigital.energy
Website: www.bigdigital.energy

WATERTOWN, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report third quarter 2026 financial results on October 29, 2026. The Company will host a video conference call and webcast at 8:30 a.m. ET that day.

To join the video call or view the livestreamed webcast, please register via this link, or visit “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. A replay of the webcast will be archived and available following the event.

About Kymera Therapeutics 
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn.

Investor Contact: 
Justine Koenigsberg
investors@kymeratx.com
857-285-5300 

Media Contact:
Matthew Henson
media@kymeratx.com
857-285-5300

NEW YORK, Oct. 22, 2026 (GLOBE NEWSWIRE) — AMC Global Media Inc. (NASDAQ: AMCX) will host a conference call to discuss results for the third quarter 2026 on Monday, November 9, 2026 at 4:30 p.m. Eastern Time. AMC Global Media will issue a press release reporting its results after the market closes.

The conference call will be webcast live via the company’s website at investors.amcglobalmedia.com.

To access the conference call via telephone, please pre-register for the call to obtain the dial-in number and a passcode.
Pre-registration instructions can be found at investors.amcglobalmedia.com under the heading “Events and Presentations.”

Internet replays will be available at investors.amcglobalmedia.com approximately two hours after the call ends.

About AMC Global Media

AMC Global Media (Nasdaq: AMCX) is home to many of the greatest stories and characters in TV and film and the premier destination for passionate and engaged fan communities around the world. The Company creates and curates celebrated series and films across distinct brands and makes them available to audiences everywhere. Its portfolio includes targeted streaming services AMC+, Acorn TV, Shudder, Sundance Now, HIDIVE and All Reality; cable networks AMC, BBC AMERICA (which includes U.S. distribution and sales responsibilities for BBC News), IFC, SundanceTV and We TV; and film distribution label Independent Film Company. The Company also operates AMC Studios, its in-house studio, production and distribution operation behind acclaimed and fan-favorite original franchises including The Walking Dead Universe and the Anne Rice Immortal Universe. AMC Global Media is headquartered in the United States, with international operations in Iberia, Latin America, Central Europe, the U.K., Australia and New Zealand.

Contacts

Investor Relations		Corporate Communications
Nicholas Seibert		Georgia Juvelis
nicholas.seibert@amcglobalmedia.com		georgia.juvelis@amcglobalmedia.com

SOUTH SAN FRANCISCO, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) — Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that it will report financial results and business highlights for the third quarter ended September 30, 2026, on Tuesday, November 3, 2026.

Denali’s management will host a conference call and webcast on Tuesday, November 3, 2026, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss third quarter 2026 financial results and provide a general business update.

The live webcast, along with a slide presentation, may be accessed through the Investors section of Denali’s website at www.denalitherapeutics.com or by clicking here. A replay of the webcast will be archived on Denali’s website for a limited time following the call.

About Denali Therapeutics

Denali Therapeutics Inc. is a biotechnology company pioneering a new class of biotherapeutics designed to cross the blood-brain barrier (BBB) using its proprietary TransportVehicle™ platform. With the first FDA-approved biologic specifically designed to cross the BBB, a clinically validated delivery platform and a growing portfolio of therapeutic candidates across all stages of development, Denali is advancing toward its goal of delivering effective medicines to transform life for people with neurodegenerative diseases, lysosomal storage disorders and other serious diseases. For more information, please visit www.denalitherapeutics.com.

Investor Contact:
Laura Hansen
hansen@dnli.com

Presentation and live Q&A to be held after market close on Thursday, November 12, 2026

BOSTON, Oct. 22, 2026 (GLOBE NEWSWIRE) — Merlin, Inc. (Nasdaq: MRLN) today announced that it has plans to host a presentation and Q&A session reviewing business performance for its third quarter ended September 30, 2026, on Thursday, November 12, 2026 beginning at 4:30 p.m. ET.

A registration link for the webcast is available here as well as on our investor relations website at https://investors.merlinlabs.com. A replay of the call and the presentation materials will be available on Merlin’s investor relations website following the call.

About Merlin
Merlin is an aerospace and defense technology company building the operating system of record for autonomous flight. Through a first-principles approach, the company is redefining what’s possible across aviation, aerospace, and defense with the goal of delivering full-stack autonomy for any aircraft, military or civilian, from takeoff to touchdown. The Merlin Pilot system powers a growing range of aircraft and mission profiles, proven through hundreds of autonomous flights from test facilities across the globe. With $100M+ total in IDIQ contract ceiling value under its C-130J autonomy program with USSOCOM, Merlin is advancing American leadership in autonomous aviation by helping to solve national security challenges through safe, reliable autonomy. To learn more, visit www.merlinlabs.com or follow us on X @merlinaero.

Contacts
Investor Relations: investor.relations@merlinlabs.com
Media: media@merlinlabs.com

LONDON, Oct. 22, 2026 (GLOBE NEWSWIRE) — Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 27, 2026 at 8:30 a.m. Eastern Time to report its third quarter 2026 financial results and recent portfolio execution.

A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.

About Kiniksa
Kiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa’s portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. For more information, please visit www.kiniksa.com.

Every Second Counts! ^®

Kiniksa Investor & Media Contact
Jonathan Kirshenbaum
(781) 829-3949
jkirshenbaum@kiniksa.com